628732-02-5

Basic information

• Product Name: 7-Iodo-1-indanone
• Synonyms: 7-Iodo-1-indanone;2,3-dihydro-7-iodoinden-1-one;7-iodo-2,3-dihydro-1H-inden-1-one;7-iodo-2,3-dihydroinden-1-one
• CAS NO: 628732-02-5
• Molecular Formula: C9H7IO
• Molecular Weight: 258.05575
• Mol File: 628732-02-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 327.3 ºC at 760 mmHg
• Flash Point: 151.7 ºC
• Appearance: /
• Density: 1.882
• Vapor Pressure: 0.000204mmHg at 25°C
• Refractive Index: 1.674
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 7-Iodo-1-indanone(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Iodo-1-indanone(628732-02-5)
• EPA Substance Registry System: 7-Iodo-1-indanone(628732-02-5)

Safety Data

• Hazardous Substances Data: 628732-02-5(Hazardous Substances Data)

Usage

General Description

7-Iodo-1-indanone is a chemical compound that consists of a six-membered ring fused to a five-membered ring with an iodo substituent at the 7-position of the indanone. It is a pale yellow solid that is primarily used as an intermediate in the synthesis of pharmaceuticals and organic compounds. This chemical has various applications in the field of organic chemistry, including as a reagent in chemical reactions and as a building block for the synthesis of more complex molecules. Its unique structure and reactivity make it an important tool for researchers and chemists in the development of new drugs and materials. Additionally, its iodo substituent adds to its versatility, allowing for further functionalization and modification to tailor its properties for specific applications. Overall, 7-Iodo-1-indanone is an important and versatile chemical compound with a wide range of applications in the field of organic chemistry and pharmaceutical synthesis.

InChI:InChI=1/C9H7IO/c10-7-3-1-2-6-4-5-8(11)9(6)7/h1-3H,4-5H2

Upstream product

• 628732-03-6 7-amino-2,3-dihydro-1H-inden-1-one 
• 77802-37-0 N-(2,3-dihydro-1H-inden-4-yl)acetamide 
• 32202-61-2 4-aminoindan 
• 58161-36-7 N-(3-oxo-2,3-dihydro-1H-inden-4-yl)acetamide 

Relevant articles and documents

Iodoindenes: Synthesis and application to cross-coupling

An expeditious synthesis of 5-, 6-, and 7-iodoindenes from the corresponding aminoindan-1-ones in more than 70% yield employing readily available precursors and ubiquitous reagents is reported. The 4-iodoindene has been prepared analogously in 40% overall yield. A three-step sequence involves diazotization-iodination of aminoindan-1-one followed by the reduction and dehydration. The iodoindenes serve as effective substrates for the regioselective Stille coupling with vinyl stannanes but isomeric mixtures are produced during Sonogashira coupling with alkynes in the presence of triethylamine.

4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.